FindTrial
Sign In

Methotrexat-Polyglutamate als Marker fuer das klinische Outcome in der Therapie der rheumatoiden Arthritis

Methotrexat-Polyglutamate als Marker fuer das klinische Outcome in der Therapie der rheumatoiden Arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-006288-56-AT
Enrollment
Unknown
Registered
2008-04-14
Start date
2008-05-14
Completion date
Unknown
Last updated
2015-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Trade Name: Ebetrexat Pharmaceutical Form: Tablet INN or Proposed INN: METHOTREXATE CAS Number: 59052 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 15-25

Sponsors

Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und Rehabilitation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Informed consent, age > 18 years, MTX naive patients, X-ray, exclusion of pregnancy, DAS-28 > 3,2, contraception Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: age 10 mg a day, alcohol abuse, low renal function, elevation of transaminases

Design outcomes

Primary

MeasureTime frame
Main Objective: Correlation between concentration of MTX polyglutamates and improvement of disease activity;Secondary Objective: Comparison of 2 different dosage schemata;Primary end point(s): intended end after 16 weeks exitus no application of medication—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026